07:36 AM EDT, 09/17/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Wednesday that a phase 3 trial of its asthma treatment Fasenra in patients with chronic obstructive pulmonary disease, or COPD, did not meet the primary endpoint despite showing numerical improvement.

The company said Fasenra's safety and tolerability in the trial was consistent with the known profile of the drug, which is currently approved as an add-on maintenance medicine for severe eosinophilic asthma.

AstraZeneca ( AZN ) said it will analyze the full data set from the trial and share the findings with the scientific community.